Mother’s Day (We See You, Mom)

MD-Featured-Image.jpg
Moms are often the chief medical officers of their households and the first line of defense when it comes to their family’s health. They are on call 24 hours, through every stage of life, and most of it goes unacknowledged because they make it look so easy. To mothers of all kinds, thank you for doing the hardest job in the world. Thank you for working tirelessly to care for others day after day, for never giving up on those who look up to you, and for understanding the powerful connection a mother figure can have in a person’s life. Happy Mother’s Day from all of us at Lehigh Valley Center For Sight.

https://www.lvcenter4sight.com/mothers-day-we-see-you-mom/

Comments

Post a Comment

Popular posts from this blog

FDA Authorizes Clinical Trial for CRISPR/Cas9 Therapy for LCA 10

Editas Medicine , a company developing gene-editing treatments, has received authorization from the US Food and Drug Administration to launch a clinical trial for its emerging CRISPR/Cas9 therapy for people with a mutation in the gene CEP290, which causes Leber congenital amaurosis 10 (LCA10). LCA causes severe vision loss or blindness at birth. Known as EDIT-101, the treatment will be evaluated in a Phase 1/2, dose-escalation clinical trial.  The company expects to enroll 10 to 20 patients. Further details and contact information for the study will be listed soon at www.clinicaltrials.gov . EDIT-101 targets a specific mutation, “c.2991+1655A>G” in intron 26, of the CEP290 gene. Editas has earned a $25 million milestone payment from Allergan as part of a drug-development alliance. “We are very pleased with this historic milestone in the treatment of inherited retinal diseases,” says Stephen Rose, PhD, chief scientific officer, Foundation Fighting Blindness. “EDIT-101 is the fi...
Read more

Cataract Surgery Leads to Longer Life in Women

Image
Written by Dr. David Evans Last modified on September 6, 2018 An article I wrote back in April described a National Bureau of Economic Research study that concluded cataract surgery patients have a life expectancy 1.8 years longer than people with cataracts who do not undergo surgery. Much of that piece focused on the finding that people, who have vision diminished by cataracts, are less likely to be active, and more likely to suffer accidental falls and related injuries. As a follow-on, a new study published in JAMA Ophthalmology suggests an even stronger link between cataract surgery and mortality risk. About the Study The genesis of this study was something completely different than evaluating effects of cataract vision loss. Its original purpose was to evaluate the effects of hormone therapy and dietary changes in postmenopausal women. That study was cut short once it was determined that hormone therapy increased the risk of vascular events. Although the hormone therapy aspect ...
Read more

Noninferiority trials confirm the IOP benefits of once-daily latanoprostene bunod

FEB 06, 2018 Glaucoma This pooled analysis assessed the efficacy and safety of latanoprostene bunod compared with timolol for the treatment of open-angle glaucoma. Study design The authors analyzed data from two phase 3, randomized, multicenter, double-masked, parallel-group, noninferiority trials (APOLLO and LUNAR), comprising 840 participants. Adults with open-angle glaucoma or ocular hypertension were randomized 2:1 to receive once-daily latanoprostene bunod (0.024%) or twice-daily timolol (0.5%) for 3 months. Outcomes Patients on latanoprostene bunod achieved a significantly lower mean IOP compared with timolol patients at 9 evaluation time points throughout 3 months of follow-up. The latanoprostene arm also had a greater number of subjects that attained a mean IOP of ≤18 mm Hg and an IOP reduction of ≥25% from baseline. The study detected a 5.9% rate of conjunctival hyperemia in the latanoprostene bunod group. Eye irritation and pain occurred in less than 5% of pa...
Read more